Method for the treatment of proliferative disorders and other pathological conditions mediated by the kinase activity of Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R
Pyrimidyl-amino-benzamide of the formula (I) ** Formula ** wherein: Py denotes 3-pyridyl, R 1 represents hydrogen, R 2 represents 5- (4-methyl-1 H -imidazol-1-yl) -3- ( trifluoromethyl) -phenyl； and R4 represents methyl； or a pharmaceutically acceptable salt thereof, for the treatment of a proliferative disorder or other pathological conditions selected from melanoma, especially melanoma that hosts c-KIT mutations, breast cancer, colon cancer, lung cancer, cancer of the Kaposi prostate or sarcoma, gastro-intestinal stromal tumors (GIST), acute myeloid leukemia (AML), leukemia that responds to an inhibition of Abl tyrosine kinase activity, such as chronic myeloid leukemia (CML), acute lymphoblastic leukemia positive for the Philadelphia chromosome (Ph + ALL), mesothelioma, systemic mastocytosis, hyper-eosinophilic syndrome (HES), fibrosis, liver fibrosis, renal fibrosis, rheumatoid arthritis, polyarthritis, scleroderma, lupus erythematosus, graft diseases against the host, neurofibromatosis , pulmonary hypertension, pulmonary arterial hypertension, Alzheimer's disease, seminomas, dysgerminomas, and psoriasis, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable carriers, is administered orally dispersed in applesauce,Pirimidil-amino-benzamida de la fórmula (I) **Fórmula** en donde: Py denota 3-piridilo, R1 representa hidrógeno, R2 representa 5-(4-metil-1H-imidazol-1-il)-3-(trifluorometil)-fenilo； y R4 representa metilo； o una sal farmacéuticamente aceptable de la misma, para el tratamiento de un trastorno proliferativo u otras condiciones patológicas seleccionadas de melanoma, en especial melanoma que aloja mutaciones de c-KIT, cáncer de mama, cáncer del colon, cáncer de pulmón, cáncer de la próstata o sarcoma de Kaposi, tumores estromales gastro-intestinales (GIST), leucemia mieloide aguda (AML), leucemia que responde a una inhibición de la actividad de cinasa de tirosina de Abl, tal como leuc
